chen hua liu - Search Results

Year	Number of Results
2002	1
2005	1
2006	5
2007	7
2008	7
2009	5
2010	5
2011	12
2012	10
2013	11
2014	11
2015	12
2016	3
2017	6
2018	13
2019	17
2020	19
2021	17
2022	18
2023	17
2024	5

1

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.

Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Chen CY, Huang JF, Dai CY, Wan-Long WL, Bair MJ, Yu ML; T-COACH Study Group. Tsai PC, et al. Among authors: liu ch. Clin Mol Hepatol. 2024 Apr 19. doi: 10.3350/cmh.2024.0038. Online ahead of print. Clin Mol Hepatol. 2024. PMID: 38637957 Free article.

2

Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.

Liu CH, Chang YP, Fang YJ, Cheng PN, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH. Liu CH, et al. J Gastroenterol. 2024 Apr 13. doi: 10.1007/s00535-024-02101-2. Online ahead of print. J Gastroenterol. 2024. PMID: 38613690

3

Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy.

Chang KC, Su TH, Liao SH, Tseng TC, Huang SC, Hsu SJ, Hong CM, Liu CH, Yang HC, Liu CJ, Kao JH. Chang KC, et al. Among authors: liu ch. J Formos Med Assoc. 2024 Feb 28:S0929-6646(24)00111-6. doi: 10.1016/j.jfma.2024.02.011. Online ahead of print. J Formos Med Assoc. 2024. PMID: 38423922 Free article.

4

HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative.

Tseng TC, Hosaka T, Liu CJ, Suzuki F, Chiang C, Hong CM, Kumada H, Yang WT, Su TH, Yang HC, Liu CH, Chen PJ, Kao JH. Tseng TC, et al. Among authors: liu ch. JHEP Rep. 2023 Nov 4;6(1):100956. doi: 10.1016/j.jhepr.2023.100956. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38089551 Free PMC article.

5

Editorial: Noninvasive tests for metabolic dysfunction-associated steatotic liver disease: A refinement of the Nash-FibroTest for type 2 diabetes mellitus.

Liu CH. Liu CH. Aliment Pharmacol Ther. 2023 Nov;58(10):1111-1112. doi: 10.1111/apt.17706. Aliment Pharmacol Ther. 2023. PMID: 37885167 No abstract available.

6

Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion.

Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, Liao SH, Hong CM, Lan TY, Yang HC, Liu CJ, Chen PJ, Kao JH. Huang SC, et al. Among authors: liu ch. Clin Gastroenterol Hepatol. 2024 Mar;22(3):581-590.e6. doi: 10.1016/j.cgh.2023.09.040. Epub 2023 Oct 21. Clin Gastroenterol Hepatol. 2024. PMID: 37871842

7

Toward the hepatitis C virus elimination in Asia: The policy forum from the 2023 Asian Pacific Association of the Study of the Liver (APASL).

Liu CH, Lin HC, Kao JH. Liu CH, et al. J Formos Med Assoc. 2023 Dec;122(12):1234-1237. doi: 10.1016/j.jfma.2023.10.005. Epub 2023 Oct 9. J Formos Med Assoc. 2023. PMID: 37821301 Free article. No abstract available.

8

High PIVKA-II level and ASAP score predict 1-year risk of hepatocellular carcinoma in non-cirrhotic chronic hepatitis B patients.

Lu YC, Su TH, Tseng TC, Hsu SJ, Liao SH, Hong CM, Liu CH, Yang HC, Liu CJ, Kao JH. Lu YC, et al. Among authors: liu ch. Am J Cancer Res. 2023 Jun 15;13(6):2588-2597. eCollection 2023. Am J Cancer Res. 2023. PMID: 37424806 Free PMC article.

9

Serial increase and high alpha-fetoprotein levels predict the development of hepatocellular carcinoma in 6 months.

Su TH, Chang SH, Chen CL, Liao SH, Tseng TC, Hsu SJ, Hong CM, Liu CH, Yang HC, Liu CJ, Chen PJ, Kao JH. Su TH, et al. Among authors: liu ch. Hepatol Res. 2023 Oct;53(10):1021-1030. doi: 10.1111/hepr.13932. Epub 2023 Jun 23. Hepatol Res. 2023. PMID: 37291079

10

Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.

Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liao SH, Hong CM, Liu CH, Lan TY, Yang HC, Liu CJ, Chen PJ, Kao JH. Huang SC, et al. Among authors: liu ch. Hepatol Int. 2023 Oct;17(5):1139-1149. doi: 10.1007/s12072-023-10545-6. Epub 2023 May 29. Hepatol Int. 2023. PMID: 37247045

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

170 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Results by year